oa Journal of Endocrinology, Metabolism and Diabetes in South Africa - Position paper of the National Osteoporosis Foundation of South Africa (NOFSA) on the use of parathyroid hormone (PTH 1-34) in the treatment of osteoporosis : position statement
|Article Title||Position paper of the National Osteoporosis Foundation of South Africa (NOFSA) on the use of parathyroid hormone (PTH 1-34) in the treatment of osteoporosis : position statement|
|© Publisher:||Medpharm Publications|
|Journal||Journal of Endocrinology, Metabolism and Diabetes in South Africa|
|Author||Stephen Hough, Brynne Ascott-Evans, Tobie De Villiers, Jan De Weerd, Graham Ellis and Stan Lipschitz|
|Publication Date||Jul 2005|
|Pages||51 - 53|
Extracted from text ... The mainstay of current therapies for osteoporosis is antiresorptive agents such as calcium, vitamin D, oestrogen, selective oestrogen receptor modulators (SERMs), calcitonin and the bisphosphonates. These drugs reduce but do not eliminate fracture risk, and do not restore lost bone structure. Anabolic agents have the potential to increase bone mineral density (BMD), restore skeletal micro-architecture and reduce fracture risk to a greater extent than the antiresorptives. Fluoride was the first anabolic agent to be used in the treatment of osteoporosis, followed by growth hormone and insulin-like growth factor. More recently, strontium, statins and parathyroid hormone (PTH) have been added ..
Article metrics loading...